BAGSVAERD, Denmark, Oct. 27 /PRNewswire-FirstCall/ -- Novo Nordisk A/S today announced its financial statement for the period January 1, 2005 to September 30, 2005.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGO ) -- Reported sales in the first nine months of 2005 increased by 15% - Sales of insulin analogs increased by 60% - Sales of NovoSeven(R) Coagulation Factor VIIa (Recombinant) increased by 15% - Sales in North America increased by 21% -- Operating profit increased by 20% to USD 1,044 million. Net profit increased by 31% to USD 791 million and earnings per share increased by 35% to USD 2.39. -- The expectation for sales growth for the full year of 2005 is increased to 13-15%, and the expectation for operating profit growth is increased to 12-15%. -- Lars Rebien Sorensen, president & CEO, said: “We are now seeing the positive effect of having a full portfolio of insulin analogs in our key European markets. With the continued roll-out of Levemir(R) (insulin detemir [rDNA origin] injection), our long-acting insulin analog, we expect to further increase our share of the global insulin analog market in the years to come.” -- Novo Nordisk has decided to conduct a global phase 3 study for the use of NovoSeven(R) in trauma - It is intended to include trauma patients from sites in the US into the ongoing global phase 3 study. - Prior to initiation of the US part of the global study, Novo Nordisk will seek to obtain an exception to the requirement for ‘informed consent’ in the US to achieve a faster patient enrolment. - The global trauma study is now expected to encompass around 1,500 patients and to take close to four years to complete.
The complete Novo Nordisk earnings announcement can be found at http://www.novonordisk.com.
Novo Nordisk is a healthcare company with an 80-year history of innovation and achievement in diabetes care. With the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems, Novo Nordisk is a world leader in diabetes care. In the United States, Novo Nordisk’s ambition is Changing Diabetes. Working as a catalyst to improve diabetes prevention and treatment, the company strives to be the preferred partner for employees, patients, healthcare providers, and others in the healthcare system who share its vision to defeat diabetes. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk’s business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs approximately 21,200 full-time employees in 78 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For global information, visit http://www.novonordisk.com; for United States information, visit http://www.novonordisk-us.com.
* For convenience, Danish kroner has been translated to USD in this release, using the average exchange rate of USD 1.00 = DKK 5.90354
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGOPRN Photo Desk photodesk@prnewswire.comNovo Nordisk A/S
CONTACT: Media: Susan Jackson, +1-609-919-7776; or Investors: MadsVeggerby Lausten, +1-609-919-7937, both of Novo Nordisk
